| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FASLG |
| Uniprot No | P48023 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 103-281aa |
| 氨基酸序列 | QIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKG GLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKM MSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLY KL |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FASLG(Fas配体)重组蛋白的示例参考文献(信息基于公开研究概括，具体文献需通过学术数据库查询)：
---
1. **文献名称**：*"Crystal structure of the soluble human Fas ligand-human Fas receptor complex"*
**作者**：Hsu, H., et al.
**摘要**：解析了人源FASLG重组蛋白与其受体FAS的复合物晶体结构，揭示了二者相互作用的分子机制，为凋亡信号传递提供了结构基础。
2. **文献名称**：*"Recombinant Fas ligand induces dendritic cell apoptosis and limits adaptive immune responses"*
**作者**：Rescigno, M., et al.
**摘要**：研究重组FASLG蛋白对树突状细胞的促凋亡作用，表明其在调控免疫耐受和炎症反应中的潜在应用。
3. **文献名称**：*"Production of functional recombinant Fas ligand in Escherichia coli"*
**作者**：Tanaka, M., et al.
**摘要**：报道了通过大肠杆菌表达系统高效制备功能性FASLG重组蛋白的方法，并验证其诱导靶细胞凋亡的活性。
4. **文献名称**：*"Fas ligand gene transfer enhances antitumor immunity in a murine melanoma model"*
**作者**：Arai, H., et al.
**摘要**：利用重组FASLG蛋白的基因疗法在黑色素瘤小鼠模型中激活肿瘤细胞凋亡，并增强抗肿瘤免疫应答。
---
**注**：以上为示例性内容，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"recombinant FASLG"或"Fas ligand protein")。
FASLG (Fas ligand), also known as CD95L or TNFSF6. is a transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It plays a critical role in regulating apoptosis (programmed cell death) and immune homeostasis by binding to its cognate receptor, FAS (CD95/APO-1). This interaction triggers the formation of the death-inducing signaling complex (DISC), activating caspase cascades that lead to controlled cell death. FASLG is primarily expressed on activated T cells, natural killer (NK) cells, and immune-privileged tissues, where it mediates immune tolerance, cytotoxic T-cell responses, and the elimination of infected or cancerous cells.
Recombinant FASLG protein is produced using genetic engineering techniques, often in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and bioactivity. The recombinant form typically includes the soluble extracellular domain (sFASLG), which retains receptor-binding capability. Researchers frequently engineer it with tags (e.g., Fc fusion, His-tag) to enhance stability, purification, or detection.
In biomedical research, FASLG recombinant protein is utilized to study apoptosis pathways, immune cell regulation, and autoimmune diseases. It has therapeutic potential in cancer immunotherapy, where modulating FASLG-FAS signaling could enhance tumor cell death or suppress excessive immune activation. Conversely, inhibitors of FASLG are explored for treating conditions like hepatitis or neurodegenerative disorders linked to aberrant apoptosis. Challenges include balancing its dual role in pro-apoptotic signaling and immune tolerance, as dysregulation may promote tumor immune evasion or autoimmune pathologies. Ongoing studies focus on optimizing its delivery and specificity for clinical applications.
×
